SEARCH

SEARCH BY CITATION

References

  • 1
    Fisher B, Carbone P, Economou SG, et al: L-phenylalanine mustard (L-PAM) in the management of primary breast cancer: A report of early findings. N Engl J Med 1975; 292: 117122.
  • 2
    Fisher B, Montague E, Redmond C, et al: Comparison of radical mastectomy with alternative treatments for primary breast cancer: A first report of results from a prospective randomized clinical trial. Cancer 1977; 39 (Suppl 6): 28272839.
  • 3
    Fisher B: Laboratory and clinical research in breast cancer - a personal adventure: The David A. Karnofsky Memorial Lecture. Cancer Res 1980; 40: 38633874.
  • 4
    Fisher B, Redmond C, Brown A, et al: Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 1981; 305: 16.
  • 5
    Fisher B: The interdependence of laboratory and clinical research in the study of metastases, in Nicolson GL, MilesL (eds): Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects. New York, Raven Press, 1984, pp 2746.
  • 6
    Fisher B, Bauer M, Margolese R, et al: Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985; 312: 665673.
  • 7
    Fisher B, Redmond C, Fisher ER, et al: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312: 674681.
  • 8
    Fisher B: The evolution of paradigms for the management of breast cancer: A personal perspective. Cancer Res 1992; 52: 23712383.
  • 9
    Consensus conference. Adjuvant chemotherapy for breast cancer. JAMA 1985; 254: 34613463.
  • 10
    Fisher B, Redmond C, Dimitrov NV, et al: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989; 320: 473478.
  • 11
    Fisher B, Dignam J, Mamounas EP, et al: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996; 14: 19821992.
  • 12
    Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479484.
  • 13
    Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89: 16731682.
  • 14
    Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 15291542.
  • 15
    Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 24832493.
  • 16
    Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 26722685.
  • 17
    Fisher B, Mamounas EP: Preoperative chemotherapy: A model for studying the biology and therapy of primary breast cancer. J Clin Oncol 1995; 13: 537540. Editorial.
  • 18
    Fisher B, Costantino J, Redmond C, et al: Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993; 328: 15811586.
  • 19
    Fisher B, Dignam J, Wolmark N, et al: Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998; 16: 441452.
  • 20
    Silverstein MJ, Poller DN, Waisman JR, et al: Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345: 11541157.
  • 21
    Silverstein MJ, Lagios MD, Craig PH, et al: A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996; 77: 22672274.
  • 22
    Fisher ER: Pathobiological considerations relating to the treatment of intraductal carcinoma (ductal carcinoma in situ) of the breast. CA Cancer J Clin 1996; 47: 5264.
  • 23
    Schnitt SJ, Harris JR, Smith BL: Developing a prognostic index for ductal carcinoma in situ of the breast: Are we there yet? Cancer 1996; 77: 21892192.
  • 24
    Sporn MB, Roberts AB: Role of retinoids in differentiation and carcinogenesis. J Natl Cancer Inst 1984; 73: 13811387.
  • 25
    Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 13711388.
  • 26
    Veronesi U, Maisonneuve P, Costa A, et al: Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352: 9397.
  • 27
    Powles T, Eeles R, Ashley S, et al: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98101.
  • 28
    Fisher B: A biological perspective of breast cancer contributions of the National Surgical Adjuvant Breast and Bowel Project Clinical Trials. CA Cancer J Clin 1991; 41: 97111.